中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
Chinese Journal of Clinicians (Electronic Edition)
2015年
20期
3666-3670
,共5页
脂肪肝%非酒精性%药物%进展
脂肪肝%非酒精性%藥物%進展
지방간%비주정성%약물%진전
Fatty liver%Nonalcoholic%Drug%Progress
非酒精性脂肪肝(NAFLD)已逐渐成为我国第一大肝病,其危害不仅可进展为非酒精性脂肪性肝炎(NASH)、肝硬化、肝细胞癌,而且作为代谢综合征(MS)的重要组分与心脑血管疾病密切相关,日益受到相关学科研究者的重视。NAFLD的治疗除了肝病本身,也应包括患者可能并存的异常代谢组分如肥胖、高脂血症、胰岛素抵抗(IR)、2型糖尿病(T2DM)等。NAFLD的治疗包括非药物治疗——生活方式改变、药物治疗两方面,前者为治疗 NAFLD 的基础。目前治疗 NAFLD的药物主要包括胰岛素增敏剂、抗氧化剂、微生态制剂、降脂药、减肥药、保肝抗炎药物及中药。
非酒精性脂肪肝(NAFLD)已逐漸成為我國第一大肝病,其危害不僅可進展為非酒精性脂肪性肝炎(NASH)、肝硬化、肝細胞癌,而且作為代謝綜閤徵(MS)的重要組分與心腦血管疾病密切相關,日益受到相關學科研究者的重視。NAFLD的治療除瞭肝病本身,也應包括患者可能併存的異常代謝組分如肥胖、高脂血癥、胰島素牴抗(IR)、2型糖尿病(T2DM)等。NAFLD的治療包括非藥物治療——生活方式改變、藥物治療兩方麵,前者為治療 NAFLD 的基礎。目前治療 NAFLD的藥物主要包括胰島素增敏劑、抗氧化劑、微生態製劑、降脂藥、減肥藥、保肝抗炎藥物及中藥。
비주정성지방간(NAFLD)이축점성위아국제일대간병,기위해불부가진전위비주정성지방성간염(NASH)、간경화、간세포암,이차작위대사종합정(MS)적중요조분여심뇌혈관질병밀절상관,일익수도상관학과연구자적중시。NAFLD적치료제료간병본신,야응포괄환자가능병존적이상대사조분여비반、고지혈증、이도소저항(IR)、2형당뇨병(T2DM)등。NAFLD적치료포괄비약물치료——생활방식개변、약물치료량방면,전자위치료 NAFLD 적기출。목전치료 NAFLD적약물주요포괄이도소증민제、항양화제、미생태제제、강지약、감비약、보간항염약물급중약。
Nonalcoholic fatty liver disease (NAFLD) is becoming the largest liver disease in China, and it has attracted more and more attention by bringing about not only liver disease, such as NASH, cirrhosis, hepatic carcinoma, but also cardiovascular and cerebrovascular diseases. So the therapy should take into account consideration not only NAFLD, but also other components of MS such as obesity, hyperlipidaemia, insulin resistance (IR), type 2 diabetes (T2DM), and so on. The therapy should include two sides, non-drug treatment-lifestyle modification, and drug treatment, and the former is basic treatment. Current drugs for treating NAFLD mainly include euglycemic agent, antioxidant, microecologics, descendens blood fat drugs, protecting liver function drugs, and traditional Chinese medicine.